Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3294078 | Gastroenterology | 2013 | 23 Pages |
Abstract
Studies on treatment of venous thrombosis or acute coronary syndrome have shown that patients treated with nOAC have an increased risk of GIB, compared with those who receive standard care. Better reporting of GIB events in future trials could allow stratification of patients for therapy with gastroprotective agents.
Keywords
NSAIDNNHACSPPIGIBNOACLMWHVKARCTRandomized controlled trialPulmonary embolismvitamin K antagonistAntithromboticDeep vein thrombosisDVTOrthopedic surgeryGastrointestinal bleedingnonsteroidal anti-inflammatory drugUlcerAcute coronary syndromeNumber needed to harmnew oral anticoagulantsconfidence intervalAtrial fibrillationComparisonProton pump inhibitorodds ratiolow-molecular-weight heparin
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
I. Lisanne Holster, Vera E. Valkhoff, Ernst J. Kuipers, Eric T.T.L. Tjwa,